TITLE

Effects of itraconazole on the steady-state plasma concentrations of bromperidol and reduced bromperidol in schizophrenic patients

AUTHOR(S)
Furukori, Hanako; Kondo, T.; Yasui, Norio; Otani, Koichi; Tokinaga, Noboru; Nagashima, Udai; Kaneko, Sunao; Inoue, Yoshimasa
PUB. DATE
September 1999
SOURCE
Psychopharmacology;1999, Vol. 145 Issue 2, p189
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Abstract Rationale: A previously reported pharmacokinetic interaction between bromperidol and carbamazepine, an inducer of cytochrome P450 (CYP) 3A4, suggests possible involvement of CYP3A4 in the metabolism of bromperidol. Objective: We investigated pharmacokinetic interaction between bromperidol and itraconazole, a potent inhibitor of CYP3A4, to clarify the involvement of CYP3A4 in the metabolism of bromperidol and its reduced metabolite. Methods: Itraconazole 200 mg/day for 7 days was coadministered to eight schizophrenic patients treated with a fixed dose of bromperidol 12 or 24 mg/day for at least 2 weeks. Blood samples were taken before and 1 week after itraconazole coadministration and 1 week after its discontinuation, together with clinical assessments using the Brief Psychiatric Rating Scale (BPRS) and the Udvalg for Kliniske Undersogelser (UKU) Side Effect Rating Scale. Results: Plasma concentrations of bromperidol during itraconazole coadministration (16.7+/-4.9 ng/ml) were significantly higher (P<0.01) than before itraconazole coadministration (8.9+/-4.4 ng/ml) and 1 week after its discontinuation (9.9+/-4.3 ng/ml). Plasma concentrations of reduced bromperidol during itraconazole coadministration (3.6+/-2.9 ng/ml) were significantly higher (P<0.01) than before itraconazole coadministration (1.8+/-1.3 ng/ml). No changes were observed in BPRS and UKU scores throughout the study. Conclusions: The pharmacokinetic interaction between bromperidol and itraconazole is probably due to the inhibitory effect of itraconazole on the metabolism of bromperidol. This study provides in vivo evidence of involvement of CYP3A4 in the metabolism of bromperidol and reduced bromperidol.
ACCESSION #
4694872

 

Related Articles

  • Pharmacokinetics of Haloperidol. Kudo, Shoji; Ishizaki, Takashi // Clinical Pharmacokinetics;1999, Vol. 37 Issue 6, p435 

    Haloperidol is commonly used in the therapy of patients with acute and chronic schizophrenia. The enzymes involved in the biotransformation of haloperidol include cytochrome P450 (CYP), carbonyl reductase and uridine diphosphoglucose glucuronosyltransferase. The greatest proportion of the...

  • Successful treatment of schizophrenia with melperone augmentation in a patient with phenotypic CYP2D6 ultrarapid metabolization: a case report.  // Journal of Medical Case Reports;2012, Vol. 6 Issue 1, p49 

    The article presents a case study of a 50-year-old Caucasian woman with acute psychotic exacerbation. She suffered from disorganized behavior and excitability, auditory hallucinations and disorganized speech. Doctors treated her with amisulpride and titrated up to a daily dosage of 1200 mg...

  • Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses. Fleeman, N; Dundar, Y; Dickson, R; Jorgensen, A; Pushpakom, S; McLeod, C; Pirmohamed, M; Walley, T // Pharmacogenomics Journal;Feb2011, Vol. 11 Issue 1, p1 

    There is wide variability in the response of individuals to standard doses of antipsychotic drugs. It has been suggested that this may be partly explained by differences in the cytochrome P450 (CYP450) enzyme system responsible for metabolizing the drugs. We conducted a systematic review and...

  • A new generation of antipsychotics: pharmacology and clinical utility of cariprazine in schizophrenia. Caccia, Silvio; Invernizzi, Roberto William; Nobili, Alessandro; Pasina, Luca // Therapeutics & Clinical Risk Management;2013, Vol. 9, p319 

    Cariprazine is a potential antipsychotic awaiting approval from the US Food and Drug Administration. It is a dopamine D2- and D3-receptor partial agonist, with higher affinity for D3 receptors, as opposed to the D2 antagonism of most older antipsychotic agents. Like most lipophilic...

  • Cytochrome P450 proteins and potential utilization in biodegradation. Guengerich, F. Peter // Environmental Health Perspectives Supplements;Jun95 Supplement 5, Vol. 103, p25 

    Discusses the potential of cytochrome P450 enzymes in biodegradation technology. High catalytic rates and facile expression in microorganisms; Three-dimensional structures of bacterial cytochrome P450 enzymes; Advantages of random mutagenesis.

  • Cytochrome P450s Potential Catalysts for Asymmetric Olefin Epoxidations. Martinez, Carlos A.; Stewart, Jon D. // Current Organic Chemistry;Mar2000, Vol. 4 Issue 3, p263 

    Cytochrome P450 monooxygenases (P450s; EC 1.14.14.1) catalyze a variety of oxidations, although they are best known for hydroxylations and olefin epoxidations. Such enzymes also might be useful in asymmetric synthesis since different forms accept aromatic polycyclic hydro-carbons, prochiral and...

  • Cytochrome P450 Gene-directed Enzyme Prodrug Therapy (GDEPT) for Cancer. L. Chen; D.J. Waxman // Current Pharmaceutical Design;Jul2002, Vol. 8 Issue 15, p1405 

    Several commonly used cancer chemotherapeutic prodrugs, including cyclophosphamide and ifosfamide, are metabolized in the liver by a cytochrome P450 (CYP)-catalyzed prodrug activation reaction that is required for therapeutic activity. Preclinical studies have shown that the chemosensitivity of...

  • Cytochrome P450 Retinoic Acid 4-Hydroxylase Inhibitors: Potential Agents for Cancer Therapy. Njar, V.C.O. // Mini Reviews in Medicinal Chemistry;Jun2002, Vol. 2 Issue 3, p261 

    Retinoids play a crucial role in cellular differentiation and proliferation of epithelial tissue and their utility in oncology and dermatology is well documented. This mini review focuses on the role of all-trans-retinoic acid (ATRA or RA), the principal endogenous retinoid and its metabolism in...

  • Mechanism-Based Inactivators as Probes of Cytochrome P450 Structure and Function. Kent, Ute M.; Jushchyshyn, Monica I.; Hollenberg, Paul F. // Current Drug Metabolism;Sep2001, Vol. 2 Issue 3, p215 

    The cytochromes P450 superfamily of enzymes is a group of hemeproteins That catalyze the metabolism of an extensive series of compounds including drugs, chemical carcinogens, fatty acids, and steroids. They oxidize substrates ranging in size from ethylene to cyclosporin. Although significant...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics